Director of Fibrosis, Hepatic and Pulmonary Research
Dr. Leeming joined Nordic Bioscience in 2004 and assumed the position as Director of Fibrosis in 2010. Her focus is on the development of serologically assessed markers to evaluate the extracellular matrix remodelling in patients with pulmonary or hepatic fibrosis for diagnosis or pharmacodynamic evaluation. Dr.Leeming is a principle inventor of PRO-C3 assay, a fibrogenesis marker used in multiple clinical trial studies. She has 150+ peer-reviewed publications.
H-index: 46. I10-index: 119. Citations: 6782